Next week marks the first anniversary of CAMP4 Therapeutics Corp. (CAMP) as a publicly listed company. Since its IPO, the stock has experienced a significant decline and trades around $2 per share, well below its initial offering price of $11.
CAMP4 is a clinical-stage biopharmaceutical company pioneering the development of antisense oligonucleotide (ASO) therapies that target regulatory RNA (regRNA) to boost gene expression and restore normal protein levels in metabolic and central nervous system (CNS) disorders, where key proteins are often underexpressed. Its lead drug candidate is CMP-CPS-001, being developed for the treatment of Urea Cycle Disorders.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.